Clinical Trial Update: Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial in Indonesia evaluating secretome from hypoxia-conditioned mesenchymal stem cells for severe COVID-19 with cytokine storm.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytokine Storm

Drugs mentioned

• Secretome of hypoxia-conditioned mesenchymal stem cells

Snippet

Sponsor: Stem Cell and Cancer Research Indonesia | Conditions: Covid-19, Cytokine Storm | Phase 2 | Status: UNKNOWN